Literature DB >> 34424763

Epitope Mapping of an Anti-Human Epidermal Growth Factor Receptor Monoclonal Antibody (EMab-51) Using the RIEDL Insertion for Epitope Mapping Method.

Ren Nanamiya1, Masato Sano1, Teizo Asano1, Miyuki Yanaka1, Takuro Nakamura1, Masaki Saito2, Tomohiro Tanaka1, Hideki Hosono1, Nami Tateyama1, Mika K Kaneko1, Yukinari Kato1,2,3.   

Abstract

The classic method for identifying the epitope that monoclonal antibodies (mAbs) bind uses deletion mutants and point mutants of the target protein. However, determining the epitope of mAbs-reactive membrane proteins is often challenging. We recently developed the RIEDL insertion for epitope mapping (REMAP) method to identify mAb-binding epitopes. Herein, we first checked the reactivity of an anti-epidermal growth factor receptor (EGFR) mAb (EMab-51) to several EGFR deletion mutants such as EGFR/dN152, EGFR/dN313, EGFR/dN370, EGFR/dN375, EGFR/dN380, and EGFR/dN482. We found the N-terminus of the EMab-51-binding epitope between residues 375 and 380 of EGFR. We next produced EGFR/dN313 mutants with the RIEDL peptide tag inserted at each possible position of 375-AFRGDSFTHTPPLDP-389. EMab-51 lost its reactivity with the mutants having a RIEDL tag inserted at each position of 377-RGDSFTHTPP-386, whereas LpMab-7 (an anti-RIEDL mAb) detected every mutant. Thus, using the REMAP method, we identified the EMab-51-binding epitope of EGFR as 377-RGDSFTHTPP-386.

Entities:  

Keywords:  EGFR; EMab-51; RIEDL tag; epitope mapping; monoclonal antibody

Mesh:

Substances:

Year:  2021        PMID: 34424763     DOI: 10.1089/mab.2021.0010

Source DB:  PubMed          Journal:  Monoclon Antib Immunodiagn Immunother        ISSN: 2167-9436


  3 in total

1.  Development of a Novel Anti-EpCAM Monoclonal Antibody for Various Applications.

Authors:  Guanjie Li; Hiroyuki Suzuki; Teizo Asano; Tomohiro Tanaka; Hiroyoshi Suzuki; Mika K Kaneko; Yukinari Kato
Journal:  Antibodies (Basel)       Date:  2022-06-08

Review 2.  Brain Cancer Chemotherapy through a Delivery System across the Blood-Brain Barrier into the Brain Based on Receptor-Mediated Transcytosis Using Monoclonal Antibody Conjugates.

Authors:  Toshihiko Tashima
Journal:  Biomedicines       Date:  2022-07-05

3.  Defucosylated mouse‑dog chimeric anti‑HER2 monoclonal antibody exerts antitumor activities in mouse xenograft models of canine tumors.

Authors:  Hiroyuki Suzuki; Tomokazu Ohishi; Teizo Asano; Tomohiro Tanaka; Masaki Saito; Takuya Mizuno; Takeo Yoshikawa; Manabu Kawada; Mika K Kaneko; Yukinari Kato
Journal:  Oncol Rep       Date:  2022-07-20       Impact factor: 4.136

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.